Avinger Beheer

Beheer criteriumcontroles 2/4

Momenteel beschikken wij niet over voldoende informatie over de CEO.

Belangrijke informatie

Jeff Soinski

Algemeen directeur

US$605.2k

Totale compensatie

Percentage CEO-salaris	66.1%
Dienstverband CEO	9yrs
Eigendom CEO	1.3%
Management gemiddelde ambtstermijn	9yrs
Gemiddelde ambtstermijn bestuur	9yrs

Recente managementupdates

Recent updates

Analyse CEO-vergoeding

Hoe is Jeff Soinski's beloning veranderd ten opzichte van Avinger's winst?
Datum	Totale vergoeding	Salaris	Bedrijfswinsten
Sep 30 2023	n/a	n/a	-US$19m
Jun 30 2023	n/a	n/a	-US$22m
Mar 31 2023	n/a	n/a	-US$22m
Dec 31 2022	US$605k	US$400k	-US$27m
Sep 30 2022	n/a	n/a	-US$28m
Jun 30 2022	n/a	n/a	-US$29m
Mar 31 2022	n/a	n/a	-US$27m
Dec 31 2021	US$595k	US$400k	-US$22m
Sep 30 2021	n/a	n/a	-US$21m
Jun 30 2021	n/a	n/a	-US$21m
Mar 31 2021	n/a	n/a	-US$22m
Dec 31 2020	US$505k	US$377k	-US$23m
Sep 30 2020	n/a	n/a	-US$23m
Jun 30 2020	n/a	n/a	-US$23m
Mar 31 2020	n/a	n/a	-US$24m
Dec 31 2019	US$607k	US$399k	-US$23m
Sep 30 2019	n/a	n/a	-US$24m
Jun 30 2019	n/a	n/a	-US$25m
Mar 31 2019	n/a	n/a	-US$26m
Dec 31 2018	US$1m	US$390k	-US$36m
Sep 30 2018	n/a	n/a	-US$39m
Jun 30 2018	n/a	n/a	-US$43m
Mar 31 2018	n/a	n/a	-US$49m
Dec 31 2017	US$522k	US$390k	-US$49m
Sep 30 2017	n/a	n/a	-US$52m
Jun 30 2017	n/a	n/a	-US$55m
Mar 31 2017	n/a	n/a	-US$55m
Dec 31 2016	US$1m	US$390k	-US$56m

Compensatie versus markt: De totale vergoeding ($USD 605.16K ) Jeff } ligt boven het gemiddelde voor bedrijven van vergelijkbare omvang in de German markt ($USD 472.15K ).

Compensatie versus inkomsten: De vergoeding van Jeff is gestegen terwijl het bedrijf verliesgevend is.

CEO

Jeff Soinski (61 yo)

9yrs

Tenure

US$605,155

Compensatie

Mr. Jeffrey M. Soinski, also known as Jeff, had been Independent Director at QSAM Biosciences, Inc. since March 02, 2022. Mr. Soinski has been Chief Executive Officer, President and Director of Avinger, In...

Leiderschapsteam

Naam	Positie	Tenure	Compensatie	Eigendom
Jeffrey Soinski	President	9yrs	US$605.16k	1.25% € 50.3k
Nabeel Subainati	VP of Finance	3.9yrs	US$295.85k	0.42% € 16.8k
Himanshu Patel	Chief Technology Officer	10.2yrs	US$423.09k	0.75% € 30.4k
Keith Schaefer	Chief Operating Officer	no data	geen gegevens	geen gegevens

9.0yrs

Gemiddelde duur

61yo

Gemiddelde leeftijd

Ervaren management: Het managementteam van VG20 is doorgewinterd en ervaren (gemiddelde ambtstermijn van 9 jaar).

Bestuursleden

Naam	Positie	Tenure	Compensatie	Eigendom
Jeffrey Soinski	President	9yrs	US$605.16k	1.25% € 50.3k
James McElwee	Independent Director	12.8yrs	US$140.00k	0.31% € 12.6k
James Cullen	Independent Non-Executive Chairman & Lead Independent Director	9yrs	US$167.50k	0.31% € 12.6k
Tamara Elias	Independent Director	4yrs	US$137.50k	0.32% € 12.8k

9.0yrs

Gemiddelde duur

70yo

Gemiddelde leeftijd

Ervaren bestuur: De raad van bestuur van VG20 wordt beschouwd als ervaren (gemiddelde ambtstermijn 9 jaar).

Avinger Beheer

Beheer criteriumcontroles 2/4

Belangrijke informatie

Recente managementupdates

Avinger, Inc., Annual General Meeting, Dec 19, 2024

Avinger, Inc. Appoints Thomas P. Davis, MD, FACC as Chief Medical Officer

Avinger, Inc., Annual General Meeting, Dec 22, 2023

Insufficient new directors

Avinger, Inc. Appoints Nabeel Subainati as the Company’s Principal Financial Officer and Principal Accounting Officer, Effective Immediately

Avinger, Inc., Annual General Meeting, Oct 14, 2022

Recent updates

Avinger Receives a Letter from the Listing Qualifications Department of the Nasdaq Stock Market

Avinger, Inc., Annual General Meeting, Dec 19, 2024

Avinger, Inc. to Report Q3, 2024 Results on Nov 07, 2024

Avinger, Inc. Initiates Full Commercial Launch of Pantheris LV Image-Guided Atherectomy Device

Avinger, Inc. Appoints Thomas P. Davis, MD, FACC as Chief Medical Officer

Avinger, Inc. to Report Q2, 2024 Results on Aug 08, 2024

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $5.996714 million.

Avinger, Inc. has filed a Follow-on Equity Offering in the amount of $6 million.

Avinger, Inc. to Report Q1, 2024 Results on May 15, 2024

Avinger, Inc. to Report Q4, 2023 Results on Mar 20, 2024

Avinger, Inc. announced a financing transaction

Avinger's Securities Would Be Delisted At the Open of Business on November 30, 2023, Unless Company Timely Requests A Hearing Before the Nasdaq Hearings Panel

Avinger's Securities Would Be Delisted At the Open of Business on November 30, 2023, Unless Company Timely Requests A Hearing Before the Nasdaq Hearings Panel

Avinger, Inc., Annual General Meeting, Dec 22, 2023

Avinger, Inc. to Report Q3, 2023 Results on Oct 26, 2023

Avinger, Inc. Initiates Full Commercial Launch of Tigereye St Image-Guided CTO Crossing Device

Second quarter 2023 earnings released: US$0.59 loss per share (vs US$0.94 loss in 2Q 2022)

Avinger, Inc. to Report Q2, 2023 Results on Jul 27, 2023

Avinger, Inc. Receives 510(K) Clearance for Pantheris LV Image-Guided Atherectomy System

Avinger, Inc. Announces Successful First Cases with Tigereye ST Image-Guided Chronic Total Occlusion Crossing Device

Avinger Receives Non-Compliance Notice from Nasdaq Regarding Stockholders’ Equity Requirement

First quarter 2023 earnings released: US$0.71 loss per share (vs US$2.33 loss in 1Q 2022)

Full year 2022 earnings released: US$4.36 loss per share (vs US$4.57 loss in FY 2021)

Insufficient new directors

Third quarter 2022 earnings released: US$0.77 loss per share (vs US$1.25 loss in 3Q 2021)

Avinger, Inc. to Report Q3, 2022 Results on Nov 09, 2022

Second quarter 2022 earnings released: US$0.94 loss per share (vs US$0.73 loss in 2Q 2021)

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $2.599923 million.

Avinger, Inc. announced that it expects to receive $2.400002 million in funding

Avinger, Inc. Appoints Nabeel Subainati as the Company’s Principal Financial Officer and Principal Accounting Officer, Effective Immediately

Avinger, Inc., Annual General Meeting, Oct 14, 2022

First quarter 2022 earnings released: US$2.33 loss per share (vs US$1.33 loss in 1Q 2021)

Avinge Receives 510(K) Clearance from the U.S. Food & Drug Administration

Third quarter 2021 earnings released: US$0.062 loss per share (vs US$0.079 loss in 3Q 2020)

Second quarter 2021 earnings released: US$0.037 loss per share (vs US$0.18 loss in 2Q 2020)

First quarter 2021 earnings released: US$0.067 loss per share (vs US$0.47 loss in 1Q 2020)

Full year 2020 earnings released: US$0.47 loss per share (vs US$3.18 loss in FY 2019)

Avinger, Inc. to Report Q4, 2020 Results on Mar 11, 2021

New 90-day high: €1.81

Avinger Regains Compliance with Nasdaq Listing Requirements

New 90-day high: €1.36

New 90-day high: €0.44

Avinger, Inc., Annual General Meeting, Dec 23, 2020

Avinger Receives Nasdaq Extension, Recommends Stockholders Vote for All Proxy Proposals

Revenue beats expectations

Third quarter 2020 earnings released: US$0.079 loss per share

Avinger, Inc. to Report Q3, 2020 Results on Nov 10, 2020

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $5.2 million.

New 90-day high - €0.58

Avinger, Inc. has completed a Follow-on Equity Offering in the amount of $6 million.

Analyse CEO-vergoeding

CEO

Tenure

Compensatie

Leiderschapsteam

Gemiddelde duur

Gemiddelde leeftijd

Bestuursleden

Gemiddelde duur

Gemiddelde leeftijd